Department of Urology, University of Verona, Piazzale Aristide Stefani, 1, 37126 Verona (VR), Italy; Department of Urology, Pitié-Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.
Department of Urology, Pitié-Salpêtrière Hospital, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.
Prog Urol. 2023 Jul;33(7):377-383. doi: 10.1016/j.purol.2023.02.005. Epub 2023 Mar 14.
Our goal was to determine the rate of complications, early revision and removal after full ambulatory implantation of bulbar AUS in men; secondly, to describe satisfaction and short-term continence rate.
Between April 2018 and April 2019, 28 consecutive patients underwent AUS implantation in a newly organised ambulatory setting. A prospective database of all included patients was established with comprehensive data collected on medical history, aetiology and severity of SUI, surgical procedures, postoperative complications and patient satisfaction.
Twenty-eight patients were included (30 consecutive procedures: 22 primary AUS placement, 6 complete revisions, 2 partial revisions), with a mean follow up of 223±220.5 days. Fourteen patients had prior radiotherapy. Readmission rate was 6.7% in the first 30 days after surgery. Both revision and removal rates were 6.7%. Complications were reported in 26.7% of procedures, mainly Clavien-Dindo I. Patient satisfaction of ambulatory surgery organisation and experience was high (87/5% satisfied or very satisfied). Full continence & social continence were achieved for, respectively, 55.6% and 88.9% of procedures.
Ambulatory placement of AUS is safe and can be performed successfully. Larger patient cohorts and randomised trials are crucial to improve knowledge on non-indications for full ambulatory AUS implantation in men.
我们的目标是确定男性经全面门诊植入球海绵体肌刺激器(AUS)后的并发症发生率、早期翻修率和移除率;其次,描述满意度和短期控尿率。
2018 年 4 月至 2019 年 4 月,28 例连续患者在新组织的门诊环境中接受 AUS 植入。为所有纳入患者建立了一个前瞻性数据库,收集了全面的病史、SUI 的病因和严重程度、手术程序、术后并发症和患者满意度等数据。
28 例患者入选(30 例连续手术:22 例初次 AUS 植入、6 例完全翻修、2 例部分翻修),平均随访 223±220.5 天。14 例患者曾接受过放疗。术后 30 天内再入院率为 6.7%。翻修和移除率均为 6.7%。26.7%的手术报告了并发症,主要为 Clavien-Dindo I 级。对门诊手术组织和体验的满意度很高(87/5%的患者满意或非常满意)。分别有 55.6%和 88.9%的手术达到完全控尿和社交控尿。
AUS 的门诊植入是安全的,并且可以成功进行。更大的患者队列和随机试验对于提高男性非全门诊 AUS 植入适应证的知识至关重要。